Chemical Compound Review:
SureCN8023 7-(4-amino-6-methyl-oxan-2- yl)oxy-6,9,11...
Synonyms:
Neuro_000133, AC1L8OJG, 63521-85-7
- Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. Braich, T.A., Salmon, S.E., Robertone, A., Alberts, D.S., Jones, S.E., Miller, T.P., Garewal, H.S. Investigational new drugs. (1986)
- Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Rose, C., Lad, T.E., Kilton, L.J., Schor, J., Rosen, S.T., Rossof, A.H., Blough, R.R., Johnson, C.M. Investigational new drugs. (1990)
- Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer. Martino, S., Samal, B.A., Redman, B., Flaherty, L., Kraut, M., Simon, M., Valdivieso, M. Breast Cancer Res. Treat. (1990)
- Phase II study of deoxydoxorubicin in patients with advanced liver cancer. Perry, D.J., Van Echo, D.A., Mick, R. Cancer treatment reports. (1987)
- Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Genne, P., Dimanche-Boitrel, M.T., Mauvernay, R.Y., Gutierrez, G., Duchamp, O., Petit, J.M., Martin, F., Chauffert, B. Cancer Res. (1992)
- Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685). Hochster, H., Hunt, M., Green, M., Parkinson, D., Smith, T. Investigational new drugs. (1990)
- Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Gambliel, H.A., Burke, B.E., Cusack, B.J., Walsh, G.M., Zhang, Y.L., Mushlin, P.S., Olson, R.D. Biochem. Biophys. Res. Commun. (2002)